Navigation Links
Trinity Biotech plc to Announce Second Quarter 2008 Financial Results on July 22, 2008
Date:7/15/2008

Conference Call Scheduled for July 22, 2008 at 11:00 am EASTERN

DUBLIN, Ireland, July 15 /PRNewswire-FirstCall/ -- Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, will report financial results for the second quarter of fiscal year 2008 on Tuesday, July 22, 2008. The Company has scheduled a conference call for that same day, Tuesday, July 22, 2008, at 11:00am EDT (4:00pm BST) to discuss the results of the quarter.

Interested parties can access the call by dialing:

USA: 877-356-5706

International: +1-706-643-0580

A simultaneous webcast of the call can be accessed at: http://www.videonewswire.com/event.asp?id=50024

A replay of the call can be accessed until July 25, 2008 by dialing:

USA: 1-800-642-1687

International: +1-706-645-9291

Conference ID #: 56210288

The webcast of the call will be available for 30 days at: http://www.videonewswire.com/event.asp?id=50024

About Trinity Biotech plc

Headquartered in Wicklow, Ireland, Trinity Biotech develops, acquires, manufactures and markets over 500 diagnostic products for the point-of-care and clinical laboratory segments of the diagnostic market. The broad line of test kits are used to detect infectious diseases, sexually transmitted diseases, blood coagulation disorders, and autoimmune diseases. Trinity Biotech sells worldwide in over 80 countries through its own sales force and a network of international distributors and strategic partners.

For further information please see the company's website: http://www.trinitybiotech.com.

Contact:

Ms. Niamh Long Joe Diaz, Joe Dorame and Robert Blum

Trinity Biotech plc Lytham Partners, LLC

Investor Relations Officer 602-889-7900

(800) 603-8076


'/>"/>
SOURCE Trinity Biotech plc
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Video: Trinity Mother Frances Neurosurgeon Using New Disc System for Patients With Degenerative Diseases of the Neck
2. Oncolytics Biotech Inc. Treats 200th Cancer Patient in Clinical Studies with REOLYSIN(R)
3. WuXi PharmaTech (NYSE: WX) Wins the 2008 Frost & Sullivan Award for Best in Class Outsourced R&D in Pharmaceuticals and Biotechnology
4. Yongye Biotechnology International, Inc. Appoints New Independent Auditor
5. N.C. Biotech Center Launches Larger Loans
6. FDA Grants Epeius Biotechnologies Rexin-G a Third Orphan Drug Designation, This Time for the Treatment of Soft Tissue Sarcomas
7. Genetic Engineering & Biotechnology News reports on novel hit-to-lead drug discovery
8. Epeius Biotechnologies Tumor-Targeted Rexin-G Receives FDA Orphan Drug Designation for the Treatment of Osteosarcoma
9. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
10. N.C. Biotechnology Center Launches Industrial Fellowship Program
11. ThirdBiotech Launches Research Institute to Promote Formation and Growth of Arizona-Based Biotech Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017  Eli Lilly and Company ... data evaluating galcanezumab for the prevention of migraine at ... will take place April 22-28, 2017, in ... four abstracts at AAN, including safety and patient outcomes ... associated with a reduction in monthly migraine headache days ...
(Date:4/20/2017)... , ... April 20, 2017 , ... ... sources for advanced technology applications, announced today that Chief Executive Officer (CEO) Debbie ... SEMI is the global industry association connecting the electronics manufacturing supply ...
(Date:4/20/2017)... , April 20, 2017 For ... focuses on novel drug development and clinical research aimed at ... Biostage Inc. (NASDAQ: BSTG), Keryx Biopharmaceuticals Inc. (NASDAQ: KERX), Kite ... ZIOP ). You can access our complimentary research reports ... ...
(Date:4/19/2017)... ... April 19, 2017 , ... Nobilis Therapeutics Announces Completion of Landmark ... Clinical Data in its Upcoming Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, ... trial assessing efficacy of its NBTX-001, a xenon-based therapeutic in the treatment of Panic ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 Research and Markets has announced the ... to their offering. ... eye tracking market to grow at a CAGR of 30.37% during ... Market 2017-2021, has been prepared based on an in-depth market analysis ... and its growth prospects over the coming years. The report also ...
(Date:4/6/2017)... Forecasts by Product Type (EAC), Biometrics, Card-Based ... & Logistics, Government & Public Sector, Utilities / Energy ... Nuclear Power), Industrial, Retail, Business Organisation (BFSI), Hospitality & ... for a definitive report on the $27.9bn Access Control ... ...
(Date:4/5/2017)... 2017 KEY FINDINGS The global ... a CAGR of 25.76% during the forecast period of ... factor for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is ... geography. The stem cell market of the product is ...
Breaking Biology News(10 mins):